Dynavax to Present at UBS 2007 Global Life Sciences Conference
BERKELEY, Calif., Sept 18, 2007 /PRNewswire-FirstCall via COMTEX News Network/ --
Dynavax Technologies Corporation (Nasdaq: DVAX) announced today Deborah Smeltzer, Vice President and Chief Financial Officer, will present an overview of the company at the UBS 2007 Global Life Sciences Conference in New York, New York on Tuesday, September 25th at 9:30 a.m. Eastern Daylight Savings Time (6:30 a.m. PDST). The presentation will be webcast.
To access the live audio broadcast and the subsequent archived audio recording of the company presentation, please log onto the company's website at http://www.dynavax.com under the "Investors'" section.
ABOUT DYNAVAX
Dynavax Technologies Corporation discovers, develops, and intends to commercialize innovative TLR9 agonist-based products to treat and prevent infectious diseases, allergies, cancer, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Our TLR9 agonists are based on immunostimulatory sequences, or ISS, which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. Our product candidates include: HEPLISAV, a hepatitis B vaccine in Phase 3; TOLAMBA(TM), a ragweed allergy immunotherapy; a therapy for non-Hodgkin's lymphoma (NHL) in Phase 2 and for metastatic colorectal cancer in Phase 1; and a therapy for hepatitis B also in Phase 1. Our preclinical asthma and COPD program is partnered with AstraZeneca. The National Institutes of Health (NIH) partially funds our preclinical work on a vaccine for influenza. Symphony Dynamo, Inc. (SDI) funds our colorectal cancer trials and our preclinical hepatitis C therapeutic program. While the NIH and SDI provide program support, Dynavax has retained rights to seek strategic partners for future development and commercialization. For more information, please visit http://www.dynavax.com.
SOURCE Dynavax Technologies Corporation
http://www.dynavax.com
Copyright (C) 2007 PR Newswire. All rights reserved
News Provided by COMTEX